Keros Therapeutics (KROS) Retained Earnings (2019 - 2025)

Keros Therapeutics' Retained Earnings history runs 7 years deep, the most recent figure standing at $1.2 billion for Q4 2025.

• Quarterly Retained Earnings rose 305.61% year-over-year to $1.2 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 billion (up 305.61% YoY) and the FY2025 annual result came in at $1.2 billion, up 305.61% from the prior year.
• Retained Earnings was $1.2 billion for Q4 2025 at Keros Therapeutics, up from -$458.3 million in the prior quarter.
• Across five years, Retained Earnings topped out at $1.2 billion in Q4 2025 and bottomed at -$568.8 million in Q4 2024.
• A 5-year average of $289.9 million and a median of $369.2 million in 2021 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2021 — Retained Earnings jumped 1143.9% — and 2023, when it sank 177.59%.
• Keros Therapeutics' Retained Earnings stood at $366.9 million in 2021, then surged by 37.86% to $505.9 million in 2022, then plunged by 175.4% to -$381.4 million in 2023, then plunged by 49.12% to -$568.8 million in 2024, then jumped by 305.61% to $1.2 billion in 2025.
• Business Quant data shows KROS's Retained Earnings at $1.2 billion in Q4 2025, -$458.3 million in Q3 2025, and $1.2 billion in Q2 2025.